Equillium (EQ) KOL Event summary

Introduction and agenda

• Event focused on the Aryl Hydrocarbon Receptor (AHR/AhR) and the EQ504 program for immune-mediated diseases, especially ulcerative colitis, with presentations from leading experts and a Q&A session.

• Presentations included scientific background, clinical rationale, and development plans, followed by a Q&A session.

KOL background and credentials

• Dr. Francisco Quintana is a leading neuroimmunologist at Harvard, recognized for pioneering AHR research and clinical translation, including the first FDA-approved AHR modulator for skin diseases.

• Dr. Brian Feagan is a gastroenterologist and clinical trialist with extensive experience in IBD, specializing in outcome measures and novel therapeutics.

Market insights and analysis

• Despite many approved drugs, remission rates in ulcerative colitis remain below 30%, highlighting significant unmet need and the lack of personalized medicine.

• New mechanisms of action are emerging, including TL1A inhibitors, oral IL-23 agents, RNA silencing, and oral alpha4beta7 antagonists, but no single therapy is curative.

• Combination therapy is gaining traction as a strategy to improve outcomes in IBD.